Related Experiment Video
Updated: Jun 21, 2026
Exploring Independent Effects of Follicle-Stimulating Hormone In Vivo in a Mouse Model
Published on: August 11, 2023
Glucocorticoid or androgen for autoimmune premature ovary failure in mice
1Department of Gynaecology and Obstetrics, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Objective:
Using mouse autoimmune premature ovary failure (POF) model to seek theoretical evidence for a possible clinical therapy of autoimmune POF with glucocorticoid (GC) or androgen.
Methods:
After autoimmune POF was induced in 60 mice by Pzp3, the mice were randomly assigned into 3 groups (n=20): Two groups were treated with GC or androgen and the control group was treated with distilled water. We observed the changes in the sexual cycles of the mice, the serum level of AzpAb, infiltration of cells positively expressing CD45 in the ovary, and pathological alterations of the ovary.
Results:
The sexual cycle of each therapy group was significantly different from that of the control group. The mean serum level of AzpAb of each therapy group was significantly lower than that of the control group, and the mean serum level of AzpAb in the GC group was significantly higher than that of the androgen group. The percentage of growing follicles in the ovary of each therapy group was significantly higher than that of the control group.Ovaries infiltrated by cells positively expressing CD45 of each therapy group were significantly fewer than those of the control group.
Conclusion:
GC or androgen in mice with autoimmune POF could obviously ameliorate the pathogenetic conditions of the disorder, and both treatments have similar therapeutic efficacy.
Insights
Glucocorticoid (GC) or androgen therapy can improve autoimmune premature ovarian failure (POF) in mice by reducing autoantibodies and ovarian inflammation. Both treatments showed similar efficacy in ameliorating the disorder's pathological conditions.
Area of Science:
- Reproductive Immunology
- Endocrinology
Background:
- Autoimmune premature ovarian failure (POF) is a condition characterized by the cessation of ovarian function due to autoimmune processes.
- Current therapeutic strategies for autoimmune POF are limited, necessitating the exploration of novel treatment options.
Purpose of the Study:
- To investigate the potential therapeutic effects of glucocorticoid (GC) and androgen on autoimmune POF in a mouse model.
- To provide theoretical evidence for the clinical application of GC or androgen in treating autoimmune POF.
Main Methods:
- Autoimmune POF was induced in mice using Pzp3.
- Mice were randomly assigned into three groups: GC treatment, androgen treatment, and a control group (distilled water).
- Evaluated parameters included sexual cycle changes, serum anti-zona pellucida antibody (AzpAb) levels, ovarian CD45+ cell infiltration, and ovarian pathology.
Main Results:
- Both GC and androgen treatments significantly altered sexual cycles compared to the control group.
- Serum AzpAb levels were significantly reduced in both treatment groups compared to the control, with GC showing a higher reduction than androgen.
- Both treatments increased the percentage of growing follicles and decreased CD45+ immune cell infiltration in the ovaries.
Conclusions:
- Glucocorticoid and androgen treatments effectively ameliorate the pathological conditions of autoimmune POF in mice.
- GC and androgen demonstrate comparable therapeutic efficacy in managing autoimmune POF.
